Merck, a pharmaceutical company, agreed to acquire Eyebiotech, a privately held ophthalmology-focused biotechnology company, for $3bn. “We continue to execute on our science-led business development strategy to expand and diversify our pipeline. The EyeBio team, under the leadership of Dr. David Guyer and Dr. Tony Adamis, has a strong track record of developing groundbreaking ophthalmology therapies. By combining our strengths, we aim to advance with rigor and speed the development of their promising pipeline of candidates targeting retinal diseases," Dean Y. Li, Merck Research Laboratories President.